MATTHEW O. NORA

• 1986-1989 Internship and Residency in Combined Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota
• 1988-1991 Fellowship in Cardiovascular Disease, Indiana University School of Medicine, Indianapolis, Indiana
• 1991-1992 Fellowship in Electrophysiology, Indiana University School of Medicine, Indianapolis, Indiana

• Illinois Medical Licensure 036-084403
• 1986 National Board of Medical Examiners, Part III
• 1989 American Board of Internal Medicine Certificate #126311
• 1993-2024 American Board of Internal Medicine, Subspecialty Board of Cardiovascular Diseases Certificate #126311
• 1994-2024 American Board of Internal Medicine, Subspecialty Board of Clinical Cardiac Electrophysiology Certificate #126311

• 1992-1/2025 Consulting Cardiologist: Good Samaritan Hospital, Downers Grove, Illinois Elmhurst Memorial Hospital, Elmhurst, Illinois Edward Memorial Hospital, Naperville, Illinois
• 1992-2002 Consulting Cardiologist: Foster G. McGaw Hospital of Loyola University Medical Center
• 1996-1/2025 Consulting Cardiologist: Central DuPage Hospital, Winfield, Illinois

• 1997-2002 Clinical Assistant Professor of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois

• 1992-2014 Physician, Midwest Heart Specialists, Downers Grove, Illinois
• 1997-2014 Director of EP Services, Midwest Heart Specialists

1982 Alpha Sigma Nu Honor Society, 1989 Presenter, Medical Grand Rounds, Indiana University School of Medicine, Indianapolis, Indiana, 1991 Kenner Award, Fellow of the Year, Indiana University School of Medicine, Indianapolis, Indiana

• 1985 Member, American Medical Association
• 1989 Fellow, American College of Cardiology

1. Izquierdo R, Sandberg L, Nora MO, Squillaci G. Hoppensteadt D, Walenga J, Fareed J,  Prinz RA: pancreatitis. Comparative study of protease inhibitors on coagulation  abnormalities in canine. Journal of Surgical Research 36:606-613, 1984.

2. Nora MO, Chandrasekaran K, Hommill SC, Heeder GS: Prolongation of ventricular  depolarization. ECG manifestation of mexiletine toxicity. Chest 95(4):925-928, 1989.

3. Nora MO, Miles WM, Klein LS, Dillon JC, Zipes DP: Alcohol ablation of ventricular  tachycardia. Journal Electrophysiology 2:456-461, 1991.

4. Nora MO, Zipes DP: 1993.Empiric use of amiodarone and sotalol. Am J Cardiol  72:62F-69F,

5. Nora MO, Elsner G, Purdy C, Zipes DP: Wide QRS rhythm rhythm due to taxine  toxicity. Journal of Cardiovascular Electrophysiology 3:59-61, 1993.

6. Anderson JL, Hallstrom AP, Epstein AE, Pinski SL, Rosenberg Y, Nora, MO, Chilson  D, Cannom DS, Moore R, and the AVID Investigators: Design and results of the  Antiarrhythmics vs Implantable Defibrillators (AVID) Registry: Circulation 99(13):1692-  1699, 1999.

1. AF Suppression™ in CRT-D: Atrial Fibrillation Suppression Pacing in Cardiac  Resynchronization Therapy Devices

Principal Investigator

2. MERLIN: Merlin Patient Care System In-Clinic Programmer Evaluation  Principal Investigator

3. A Phase I Study To Evaluate The Pharmacokinetic And Hemodynamic Effects Of  Bolus Doses Of Carperitide (Hanp) In Subjects With Congestive Heart Failure  Principal Investigator

4. Home AED Trial

Principal Investigator

5. Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization  Therapy (MADIT – CRT)

Sub Investigator

6. Clinical Research Evaluation of the ASSURE Device Atrial and Ventricular  Tachyarrhythmia Therapies. (REASSURE AV)

Sub InvestigatorA Clinical Study Evaluating Cardiac

7. Evaluation of Housecall Plus™ Remote Monitoring System

Sub Investigator

8. Left Ventricular-Based Cardiac Stimulation Post-AV Node Ablation Evaluation (PAVE)  Sub Investigator

9. Device Evaluation of Contak Renewal 2/4/4HE and Easytrak 2: Assessment of Safety  and Effectiveness in Heart Failure. (DECREASE HF)

Sub Investigator

8. Prevention of Sudden Cardiac Death Heart Failure Trial (SCD- HeFT)  Principal Investigator

9. MIRACLE ICD InSync® ICD Clinical Study: Resynchronization Therapy for Heart  Failure Patients with ICD Indications.

Principal Investigator

10. A Placebo-Controlled Double-Blind, Parallel Arm Trial to Assess the Efficacy of  Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death  From Any Cause in Patients with Atrial Fibrillation (AF/AFL) (ATHENA)  Principal Investigator

11. Tendril FSR Model 1699T Leads: Bipolar Far-Field Sensing Reduction Endocardial,  Steroid-Eluting, Active Fixation Leads (FSR LEAD)

Sub-Investigator

12. FREEDOM – Frequent Optimization Study Using the QuickOpt™ Method  Sub-Investigator